NanoString Technologies Revenue and Competitors

Seattle, WA USA

Location

$731.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • NanoString Technologies's estimated annual revenue is currently $142.9M per year.(i)
  • NanoString Technologies received $56.0M in venture funding in June 2017.
  • NanoString Technologies's estimated revenue per employee is $192,083
  • NanoString Technologies's total funding is $731.4M.

Employee Data

  • NanoString Technologies has 744 Employees.(i)
  • NanoString Technologies grew their employee count by -7% last year.

NanoString Technologies's People

NameTitleEmail/Phone
1
Product OwnerReveal Email/Phone
2
Chief Commercial Officer (CCO)Reveal Email/Phone
3
Chief Commercial Officer (CCO)Reveal Email/Phone
4
Chief Research EngineerReveal Email/Phone
5
CFOReveal Email/Phone
6
VP FinanceReveal Email/Phone
7
VP Customer ExperienceReveal Email/Phone
8
VP Quality Assurance and Regulatory AffairsReveal Email/Phone
9
Head Bulk Genomics Business Unit, Global Sales LeadReveal Email/Phone
10
VP/Global Head Human Resources-CHROReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$5.1M336%N/AN/A
#4
$5.7M3742%N/AN/A
#5
$1.4M18-10%N/AN/A
#6
$3.7M48-21%$16MN/A
#7
$1.1M70%N/AN/A
#8
$0.8M5-81%N/AN/A
#9
$2.5M16-27%N/AN/A
#10
$0.8M5-17%N/AN/A
Add Company

What Is NanoString Technologies?

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the nCounter Dx Analysis System. The company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. The company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The nCounter-based Prosigna Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic assay to be marketed through the company's diagnostics business. The nCounter Dx Analysis System is FDA 510(k) cleared for use with the Prosigna Breast Cancer Prognostic Gene Signature Assay. To date, it has not been cleared by the FDA for other indications or for use with other assays. Leading researchers are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

$731.4M

Total Funding

744

Number of Employees

$142.9M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

NanoString Technologies News

2022-04-20 - NanoString Technologies, Inc. (NASDAQ:NSTG) Expected to ...

NanoString Technologies, Inc develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and...

2022-04-06 - NanoString Technologies Announces Preliminary Revenue ...

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company provides three...

2022-03-30 - NanoString Launches New nCounter Pro Analysis System

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company provides three...

2021-11-09 - NanoString Releases High-Resolution FFPE Tissue Dataset Generated Using New CosMx Spatial Molecular Imager

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the first public release of data generated by the CosMx™ Spatial Molecular Imager (SMI). The data represents the first high-plex, single cell in situ d ...

2021-09-02 - NanoString Presents: Advancing Science – A Virtual Immunology Conference: September 14, 2021 (*September 15, 2021, Asia-Pacific)

The Virtual Immunology Conference is the premier event to learn and discuss novel advances in immunology research. SEATTLE (PRWEB) September 02, 2021 NanoString Technologies, a leading provider of life science tools for translational research, is bringing together thousands of industry leaders ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$254.5M7486%N/A
#2
$35M7548%N/A
#3
$193.5M768N/AN/A
#4
$193.5M768N/AN/A
#5
$315.5M7775%N/A

NanoString Technologies Funding

DateAmountRoundLead InvestorsReference
2005-04-28$3.8MAArticle
2007-06-25$8.0MBOVP Venture Partners, Draper Fisher JurvetsonArticle
2009-06-09$30.0MCClarus VenturesArticle
2011-11-08$20.0MUndisclosedBioMed VenturesArticle
2012-04-04$15.0MUndisclosedOxford Finance, Valley Bank ProvideArticle
2012-12-04$15.3MUndisclosedMorgan Stanley Expansion Capit, AllianceBernstein AlternativeArticle
2017-06-06$56.0MUndisclosedArticle